Global Shift: PCOS Renamed to PMOS for Better Diagnosis and Care

Polycystic ovary syndrome, affecting 170 million women globally, is being renamed to polyendocrine metabolic ovarian syndrome (PMOS) to enhance diagnosis and treatment. The revision aims to address the condition's wide-ranging hormonal and metabolic impacts, moving away from the misleading focus on ovarian cysts.

On Tuesday, researchers announced a pivotal change in the medical terminology for a condition affecting 170 million women worldwide. Polycystic ovary syndrome, or PCOS, is set to be renamed polyendocrine metabolic ovarian syndrome, or PMOS, aiming to improve diagnosis and care.

This rebranding was spearheaded by a global coalition, including patients, clinicians, and medical organizations, to better illustrate the hormonal and metabolic challenges of the condition. The misleading association of the name with ovarian cysts often leads to diagnostic errors and fragmented care, experts reported at the European Congress of Endocrinology in Prague.

The transformation involves more than just a name change; it indicates a comprehensive shift towards better integration in health systems. With symptoms like infertility and metabolic disturbances, the move towards adopting PMOS terminology aims to improve understanding and management, backed by extensive surveys and workshops globally.